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Heparanase is a promising anticancer target because of its
involvement in cancer invasion and metastasis. Heparanase
cleaves heparan sulfate (HS), a sulfated polysaccharide, and acti-
vates a series ofHS-mediated cell proliferation and angiogenesis
processes. Understanding the substrate specificity of hepara-
nase will aid the discovery of heparanase inhibitors. Here, we
sought to determine the specificity of heparanase using syn-
thetic polysaccharide substrates. The substrates were prepared
using purifiedHS biosynthetic enzymes. Using these substrates,
we were able to dissect the structural moieties required for
heparanase. Our data suggest that heparanase cleaves the link-
age between a GlcA unit and anN-sulfo glucosamine unit carry-
ing either a 3-O-sulfo or a 6-O-sulfo group. In addition, hepara-
nase cleaves the linkage of a GlcA unit andN-sulfo glucosamine
unit with a 2-O-sulfated GlcA residue, not a 2-O-sulfated IdoA
residue, in proximity. We also discovered that the polysaccha-
ridewith repeating disaccharide units of IdoA2S-GlcNS inhibits
the activity of heparanase. Our findings advance the under-
standing of the substrate specificity of heparanase and identify a
lead compound for developing polysaccharide-based hepara-
nase inhibitors.
Heparanase cleavesheparan sulfate (HS),3which is expressed in
avarietyof cells and tissues.Thedegradationbyheparanase results
in smaller HS fragments ranging in size from 10 to 20 sugar units,
and these fragments modulate the functions of growth factors
and growth factor receptors (1). Consequently, heparanase
plays regulatory roles in several pathophysiological processes
such as tissue remodeling, inflammation, angiogenesis, metas-
tasis, and tumor progression (2–4). The contribution of
heparanase to tumor formation, invasion, and metastasis has
beennoted. The level of heparanase is up-regulated in a number
of primary tumors such as head and neck, pancreatic carci-
noma, hepatocellular carcinoma, and several cultured human
tumor cell lines (5–9). The overexpression of heparanase has
been correlated to an invasive phenotype in experimental ani-
mals (10). Furthermore, heparanase has been linked to tumori-
genesis in a wide array of cancers, such as breast, prostate, and
colon (11–21). Thus, there is considerable interest to find the
inhibitor of heparanase for anticancer drug development.
HS is comprised of repeating disaccharide units of glucu-
ronic (GlcA)/iduronic (IdoA) acid 134 linked to glucosamine
of which the residue is N-acetylated (GlcNAc), N-sulfated
(GlcNS), or N-unsubstituted (GlcNH2) (22). The biosynthesis
of HS is carried out by an array of biosynthetic enzymes to
decorate the end products with sulfo groups and IdoAunits. HS
biosynthesis begins with the alternating addition of GlcA and
N-acetyl glucosamine by glycosyltransferases, which are
encoded by EXT1 and EXT2 genes. Concomitantly with chain
elongation, the polysaccharide ismodified byN-deacetylase/N-
sulfotransferase, which converts GlcNAc to a GlcNS unit. The
GlcA unit is then converted to IdoA by altering the configura-
tion at the C5 position by C5-epimerase (23). Further O-sulfa-
tions are carried out by 2-O-sulfotranferase (2-OST), 6-O-sul-
fotransferase (6-OST), and 3-O-sulfotransferase (3-OST) to
form the highly sulfated products. The sulfation patterns and
the position of the IdoA residue of HS give rise to the selectivity
that allows HS to bind to a variety of ligands and play a regula-
tory role in physiological processes such as embryogenesis (24)
and pathological roles such as tumorigenesis (25).
To date, many efforts have been made to elucidate the sub-
strate recognition mechanism of heparanase. It has been per-
ceived that heparanase acts on specific sulfated saccharide
sequences (26). Pikas et al. (27) examined the specificity of
heparanase utilizing an octasaccharide and a capsular polysac-
charide of Escherichia coli K5 strain, as well as its chemically
modified derivatives. This study revealed that O-sulfo groups
are important for heparanase recognition but not N-sulfation.
The Pikas report also indicated that 2-O-sulfation on the IdoA
or GlcA was essential for recognition by heparanase. Several
years later, Okada et al. (28) further detailed the substrate spec-
ificity of heparanase using tetra- and hexasaccharides. The data
from this report suggest the following: 1) theminimumhepara-
nase recognition site is a trisaccharide; 2) heparanase cleaves
the linkage of GlcA and GlcNS that is 6-O-sulfated or 3,6-O-
disulfated; and 3) the 2-O-sulfated iduronic acid (IdoA2S) is
nonessential for heparanase cleavage. Despite their success, the
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results from these reports cannot provide a clear picture of
which monosaccharide sequences are recognized by hepara-
nase beyond a disaccharide/trisaccharide level.
In this manuscript, we sought to define the substrate speci-
ficity of heparanase utilizing synthetic polysaccharide sub-
strates. The polysaccharides were prepared by purified HS bio-
synthetic enzymes, and each polysaccharide substrate has
unique sulfation patterns (29). Utilizing this approach, we syn-
thesized a library of structures. To investigate the effects of
certain saccharide structures that are present in low abun-
dance, we also prepared the polysaccharides with repeating
units of GlcA-GlcNS3S and GlcA2S-GlcNS. The polysaccha-
ride substrates were exposed to heparanase, and the extent of
the degradation was monitored by gel permeation chromatog-
raphy. Instead of recognizing specific sulfated monosaccharide
sequences, our data suggest that heparanase reads certain sul-
fation types. It cleaves the linkage of GlcA-GlcNS6S (or -3S) or
the linkage of GlcA-GlcNS with a GlcA2S residue in the vicin-
ity. Furthermore, the polysaccharide containing IdoA2S-
GlcNS is a potent inhibitor of heparanase. Our data provide a
systematic view of the effects of sulfation pattern on the suscep-
tibility to heparanase and uncover a lead compound for devel-
oping a substrate-like inhibitor of heparanase.
EXPERIMENTAL PROCEDURES
Preparation of Heparanase Expression Plasmid—The bac-
teria clone (clone 6250265) containing the full-length hu-
man heparanase was purchased from Open Biosystems
(Huntsville, AL). Two primers, 5-ATATTAGAATTCATG
CTGCTGCGCTCGAAGCCT-3 and 5-ATAAATTCTA-
GAGATGCAAGCAGCAACTTTGGC-3, were synthesized,
where the restriction sites of EcoRI and XbaI are underlined.
The PCR reaction was performed to amplify heparanase
using the conditions as follows: 95 °C for 2 min, followed
by 30 cycles of 95 °C for 30 s, 55 °C for 30 s, 68 °C for 2 min,
and 68 °C for 10 min. The resulting PCR product was cloned
into the pcDNA3.1-A vector (Invitrogen) using EcoRI and
XbaI sites to form a heparanase Myc-tagged protein. The plas-
mid (heparanase/pcDNA3.1) was confirmed by sequencing
analysis (Genomic Analysis Core Facility, University of North
Carolina).
Expression of Recombinant Heparanase in CHO Cells—Wild
type Chinese hamster ovary (CHO) cells were transiently
transfected with heparanase/pcDNA3.1 according to a
standard protocol. Briefly, CHO cells were cultured in F-12
medium supplemented with 10% fetal bovine serum andmain-
tained at 37 °C in a 5% CO2 humidified incubator. About 2 
105 cells were seeded per well (diameter, 3.5 cm) in a 6-well
plate. Upon90–95%confluence, transfectionwasperformedwith
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions.After48h, cellswereharvestedwithacell scraperand
centrifuged (2,000 rpm for 8min). The cellswere lysed in 100l of
lysis buffer (1% Triton X-100, 1.5 M sucrose, and 1 mM phenyl-
methylsulfonyl fluoride) on ice for 1 h. The lysate was centrifuged
(at 12,000 rpm for 10 min at 4 °C), and the supernatant was col-
lected. The expression level of heparanase in both cell lysate and
medium was assessed byWestern analysis using 10% SDS-PAGE
blotted with mouse anti-Myc monoclonal antibody and anti-
mouse horseradish peroxidase (Invitrogen). We only detected
heparanase in cell extract.
Preparation of Metabolically 35S-labeled HS from CHOCells—
Confluent cells (T75 flask) were incubated with 0.5 mCi/ml
of sodium [35S]sulfate (MD Biomedicals) for 16 h at 37 °C in
5 ml of F-12 medium supplemented with 10% dialyzed fetal
bovine serum (26). To the medium, 1 ml of solution containing
1 mg/ml Pronase (Sigma), 240 mM sodium acetate, pH 6.5, and
1.92 M NaCl was added and incubated at 37 °C overnight. The
sample was then purified by a DEAE column that was equili-
brated with a buffer containing 20 mM NaAcO, pH 5, 150 mM
NaCl. The HS was then eluted with a buffer containing 20 mM
NaAcO, pH 5, 1 M NaCl. The purified [35S]HS was dialyzed
against 50mM ammonium bicarbonate using a 3,500molecular
weight cut-off membrane. The sample was treated with 0.1 M
NaOHand 9mM sodiumborohydride at 46 °C for 16 h to cleave
the linkage between HS and the core protein. The sample was
finally treatedwith chondroitinase ABC (20 units/ml; Sigma) to
remove chondroitin sulfate. The 35S-labeled HS was dried and
ready for the subsequent analysis.
Assaying for Heparanase Enzymatic Activity—Enzymatic
reactions were carried out in 50 mM MES, pH 6.0, containing
50,000 counts permin of [35S]HS and 0.2g of heparanase. The
reactionwas incubated for 24 h at 37 °C followed by subsequent
heating (100 °C, 5 min) and centrifugation (13,200 rpm for 5
min) to precipitate the insoluble material. The products were
analyzed by gel permeation chromatography (GPC)-HPLC.
Briefly, the reaction was injected into a TSK-gel G3000SWXL
column (TosohBiosciences), whichwas equilibrated by a buffer
containing 20mMMOPS, 400mMNaCl, pH 7.0, at a flow rate of
1.0 ml/min. The performance of the GPC-HPLC was assessed
using a set of protein standards, including blue dextran (2000
kDa), -amylase (200 kDa), bovine serum albumin (66 kDa),
carbonic anhydrase (29 kDa), cytochrome c (12.4 kDa), and
sodium azide (0.065 kDa). All these standards were purchased
from Sigma. A shift of the 35S-labeled peak toward the lower
molecular range indicated heparanase cleavage.
Preparation of 35S-labeled HS Polysaccharide Substrates—
All synthetic polysaccharides started from heparosan, which
was purified from themedia of E. coliK5 using a DEAE column
(30). 6-O-Sulfo heparosan (compound 2) was prepared by incu-
bating heparosan and 6-OST-3. Briefly, 1 g of heparosan, 0.3
mg/ml of 6-OST-3 and 50 M [35S]PAPS (1.3 103 cpm/pmol)
weremixed in 100l of reaction buffer containing 50mMMES,
0.5% Triton X-100, pH 7.0. The reaction was incubated at 37 °C
for 16 h. The product was purified by a DEAE column.
Alternatively, heparosan was converted to N-sulfo hep-
arosan (compound 3) through chemical deacetylation and
enzymatic N-sulfation. To prepare deacetylated heparosan,
heparosan (20 mg/ml) was incubated in 0.1 M NaOH and 0.1 M
NaBH4 and incubated at 50 °C for 3 h. The reaction was
neutralized with acetic acid and then dialyzed against 50 mM
ammonium bicarbonate using a 3500 molecular weight cut-
off membrane. The polysaccharide was then incubated in 2 M
NaOH at 68 °C for 3 h and then neutralized by concentrated
HCl (37%, w/w) followed by dialysis using a 3500 molecular
weight cut-off membrane. The deacetylated heparosan (10
g/ml) was N-sulfated using 0.075 mg/ml of NST and 50 M
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[35S]PAPS (4.8  102 cpm/pmol) in 100 l of reaction buffer
containing 50 mM MES, 0.5% Triton X-100, pH 7.0. The
reaction was incubated at 37 °C for 16 h. The product was
purified by a DEAE column.
The N-sulfo heparosan (compound 3) was 6-O-sulfated
using a mixture of 6-OST-1 and 6-OST-3 to prepare N-sulfo
6-O-sulfo heparosan (compound 4). In brief, 1 g of N-sulfo
heparosan (compound 3) was incubated with 0.2 mg/ml of
6-OST-1, 0.3mg/ml of 6-OST-3 and 50M [35S]PAPS in 100l
reaction buffer. After incubation at 37 °C for 16 h, the product
was purified by DEAE chromatography.N-sulfo 3-O-sulfo hep-
arosan (compound 5) was prepared similar to compound 4 by
replacing 6-OST-1 and 6-OST-3 with 0.1 mg/ml of 3-OST-1.
To prepare N-sulfo 2-O-sulfo heparosan (compound 6),
N-sulfo heparosan (compound 3) was modified with 0.15
mg/ml of 2-OST and 50 M [35S]PAPS in 100 l of reaction
buffer. N-sulfo 2-O-sulfo heparan (compound 7) was prepared
using a mixture of 0.1 mg/ml of C5-epimerase and 0.15 mg/ml
of 2-OST with 50 M [35S]PAPS in 100 l of reaction buffer.
The reactions were incubated at 37 °C for 16 h, and the prod-
ucts were purified by a DEAE column.
Analytical Procedures for Synthetic Polysaccharides—To
verify the structural composition of the enzymatically syn-
thesized substrates, disaccharide analysis was performed
using two distinct techniques: heparin lyase digestion and
nitrous acid degradation. For heparin lyase digestion, sul-
fated heparosan (1–10 g) was degraded with a mixture of
heparin lyase I, II, and III (0.1 mg/ml each) in 300 l of 50mM
sodium phosphate, pH 7.0 (31). The digestion was incubated
at 37 °C overnight. The resultant disaccharides were isolated
FIGURE 1. Preparation and characterization of recombinant heparanase. Plasmid expressing C-terminal Myc-tagged heparanase (Hep.) was transiently
transfected into CHO cells. Heparanase was harvested from cell extracts. Panel A shows the presence of the 65-kDa unprocessed heparanase protein (top band)
and the active 50 kDa protein after proper intracellular processing (bottom band). Panel B indicates that the expressed recombinant heparanase protein
possessed enzymatic activity. This result is shown by the shift in the GPC chromatogram. The molecular mass of the cleavage products was measured by gel
filtration chromatography using a TSK-gel G3000SWXL column. The molecular mass standards used were -amylase (200 kDa), bovine serum albumin (66 kDa),
carbonic anhydrous (29 kDa), and cytochrome c (12.4 kDa). The void volume (V0) and total column volume (Vt) were determined by resolving blue dextran (2000
kDa) and sodium azide (65 Da), respectively. Panel C shows the size of the uncleaved material (69 kDa) versus the cleaved material (10 kDa) as indicated by
arrows. cpm, counts per min.
Probing the Substrate Specificity of Heparanase
14506 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 19 • MAY 7, 2010
using a BioGel P-2 column followed by disaccharide analysis
using reverse phase ion-pairing HPLC as described (31).
To determine the presence of GlcA2S versus IdoA2S, nitrous
acid degradation was performed by deaminative cleavage (pH
1.5) at the glycosidic linkage containing N-sulfo glucosamine
units (32). After degradation, the disaccharides were isolated
using a BioGel P-2 column and analyzed using a C18 column
(Grace Davison Discovery Sciences) under reverse phase ion-
pairing-HPLC conditions.
Inhibition of the Activity of Heparanase—The enzymatic
reactions were assembled in a same way as described under
“Experimental Procedures” except with the addition of com-
pound2,3,7, or PI-88 (0.5–50g/ml). Complete inhibitionwas
indicated by the identical elution profiles of 35S-labeled sub-
strate with or without heparanase cleavage on GPC-HPLC.
RESULTS
Expression ofHeparanase inCHOCells—Recombinant hepara-
nase was transiently expressed in CHO cells by transfecting
the plasmid expressing Myc-tagged
heparanase. The level of heparanase
was determined by Western analy-
sis (Fig. 1A). As expected, hepara-
nase is synthesized as a 65-kDa
protein (pro-heparanase), and a
processed heparanase appeared at
50 kDa. It was reported that the N
terminus is cleaved by cathepsin L
to yield an active enzyme with a
molecularmass of 50 kDa (3, 26, 33).
The recombinant enzyme was incu-
bated with 35S-labeled HS isolated
from CHO cells to confirm the
enzymatic activity. Indeed, the size
of the degraded [35S]HS migrated
toward smaller molecular mass
range after heparanase treatment as
determined by GPC-HPLC (Fig.
1B). Using protein molecular mass
standards, we estimated the molec-
ular mass of uncleaved HS was 69
kDa, whereas the molecular mass
of heparanase-degraded HS was
10 kDa (Fig. 1c). Further analysis
of the size of heparanase-digested
HS using BioGel P-10 suggested that 80% of the product
are larger than decasaccharide (supplemental Fig. 1). We also
observed a slight shift in the chromatogram of the 35S-labeled
HS treated with pcDNA3.1-transfected cell extract (Fig. 1B).
This observation is not unanticipated because CHO cells
express endogenous levels of heparanase (34). We also
observed the extent of the cleavage of 35S-labeledHS correlated
with the amount of cell extracts in the reaction (data not
shown). We estimated that the level of heparanase from the
overexpressed CHOcells was 60-fold higher than from thewild
type CHO cells.
Preparation of Polysaccharide Substrates with Different Sul-
fation Patterns—We employed a library of polysaccharides
to interrogate the substrate specificity of heparanase. The
polysaccharides were prepared using different combinations of
HS biosynthetic enzymes, allowing us to engineer the sulfation
pattern in the polysaccharides. A total of seven polysaccharide
constructs were prepared as shown in Fig. 2. The level of sulfa-
tions for each polysaccharide construct was estimated based on
the number of [35S]sulfo groups transferred to the polysaccha-
ride (Table 1). Disaccharide analysis of the polysaccharides was
also conducted, confirming the presence of the desired sulfa-
tion types and levels (supplemental Fig. 2).
The Contribution of Sulfation on the Glucosamine Residue to
the Cleavage by Heparanase—We examined the effect of N-
andO-sulfation of glucosamine residue on the susceptibility to
heparanase digestion. Two groups of substrates were prepared.
Group I contains a single type of sulfation of the polysacchar-
ides, including 6-O-sulfo heparosan (2) and N-sulfo heparosan
(3). Group II contains two types of sulfation on the glucosamine
units, including N-sulfo 6-O-sulfo heparosan (4) and N-sulfo
3-O-sulfo heparosan (5). To facilitate the analysis, 35S-labels
FIGURE 2. Scheme for the synthesis of polysaccharide substrate. Heparosan, a capsular polysaccharide
isolated from E. coli K5, was used as the starting material for substrate design. The synthesis was carried out
using purified recombinant HS biosynthetic enzymes. The procedures for the enzymatic synthesis of polysac-
charide substrates are described under “Experimental Procedures.” The polysaccharide substrates were puri-
fied using DEAE columns, and the desired structures were confirmed by disaccharide analysis. C5-epi, C5-epi-
merase; NST, N-sulfotransferase.
TABLE 1
Summary of the modification to synthetic polysaccharides and the











1 GlcA-GlcNAc6S 0.4 
2 GlcA-GlcNS 2.4 
3 GlcA-GlcNS6S 1.2 
4 GlcA-GlcNS3S 0.4 
5 GlcA2S-GlcNS 1.8 
6 IdoA2S-GlcNS 2.3 
a The boldface font represents the enzymatic modification within the substrate.
b The represents those structures that were cleaved, whereas () represents those
structures that are resistant to cleavage.
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were introduced to the substrates. Because heparosan (1) was
known to be resistant to the digestion (27), we did not test its
susceptibility to heparanase digestion.
Both 6-O-sulfo heparosan and N-sulfo heparosan were ex-
posed to heparanase, and the products were analyzed by
GPC-HPLC. The elution profiles of the 35S-labeled sub-
strates with or without heparanase from GPC-HPLC nearly
overlapped, suggesting that neither of the substrates was
susceptible to the digestion of heparanase (Fig. 3, A and B). It
has also been reported that N-sulfo heparosan is not a sub-
strate for heparanase (27, 28). Thus, our data confirmed the
previous findings. Previous substrate studies also suggested
that heparanase is unable to cleave the linkage of GlcA-
GlcNAc6S using the model oligo-
saccharide substrates (28). Thus,
our results are consistent with the
reported conclusion derived from
using oligosaccharide substrates.
We next tested the substrates
containing two types of sulfation,
namely N- and O-sulfation on glu-
cosamine units (4 and 5). Both 4
and 5 differed in the position of
O-sulfo group on glucosamine
units. N-sulfo 6-O-sulfo heparosan
(4) contained the O-sulfo group at
the 6-OH position, whereasN-sulfo
3-O-sulfo heparosan (5) contained
theO-sulfo group at the 3-OH posi-
tion (Fig. 2). The GPC-HPLC analy-
sis of 4 and 5 (with or without
heparanase treatment) revealed that
the molecular mass of the polysac-
charides were reduced, suggesting
that both substrates were suscepti-
ble to the digestion of heparanase
(Fig. 3, C and D). Because substrate
4 was an excellent substrate for
heparanase and can be prepared
readily in a large quantity, we used it
as a substrate for the subsequent
inhibition experiments as described
below. It should be noted that sub-
strate 5 contains the domain that is
part of antithrombin-binding site of
theHS carrying anticoagulant activ-
ity (35). It has been demonstrated
that heparanase cleaves the oligo-
saccharide containing a linkage of
-GlcA-GlcNS3S6S- (27); however,
whether heparanase degrades the
linkage of -GlcA-GlcNS3S- has not
been reported. Taken together, our
results demonstrate that both N-
and O-sulfations (either 6-O-sulfa-
tion or 3-O-sulfation) are required
for the cleavage by heparanase.
Effects of 2-O-Sulfation on the
Susceptibility of Heparanase Digestion—The contribution of
O-sulfation on the hexuronic acid unit to heparanase diges-
tion was also investigated. Here, we prepared the substrate
containing the -GlcA2S-GlcNS- (6) domain and the sub-
strate containing the -IdoA2S-GlcNS- (7) domain. Substrate
6 was found to be cleaved by heparanase as demonstrated by
the GPC analysis (Fig. 3E), suggesting introducing 2-O-sulfo
groups to the GlcA unit conferred the susceptibility to the
digestion of heparanase. The results of the analysis of
heparanase-treated substrate 7 revealed a starkly different
situation. The 35S-labeled substrate 7 that carries the repeat-
ing unit of IdoA2S-GlcNS is completely resistant to the
heparanase digestion (Fig. 3F).
FIGURE 3. GPC-HPLC profiles of polysaccharide substrates with or without heparanase digestions. Site-
specifically 35S-labeled polysaccharide substrates were incubated with 0.2 g/ml of heparanase to determine
the reactivity to the cleavage by the enzyme. The samples were then resolved by GPC-HPLC. Panels A–F show
the profiles of substrates 2, 3, 4, 5, 6, and 7 with or without heparanase treatment. cpm, counts per min.
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It is very important to note that a partial cleavage of substrate
7 was observed if the substrate was prepared using wild type
2-OST (supplemental Fig. 3). We conclude that the cleavage is
due to the fact that a low level of -GlcA2S-GlcNS- is present in
the substrate because wild type 2-OST sulfates both IdoA and
GlcA (36). To overcome the contamination of GlcA2S in sub-
strate 7, we utilized 2-OSTmutant (2-OST Y94I), which exclu-
sively sulfates the IdoA but not GlcA (37).
Heparanase Cleaves the Linkage That Contains Nonsulfated
Glucuronic Acid—We then proved that the linkage of -GlcA-
GlcNS (3S or 6S)- was indeed susceptible to the heparanase
cleavage. To this end, we prepared two site-specific, 35S-labeled
substrates 4 and 5, where the 35S-label was located at 6-OH
position or 3-OH position, respectively. The polysaccharides
were digested with heparanase followed by nitrous acid degra-
dation. The degraded products were analyzed for the presence
of 35S-labeledmonosaccharide as illustrated in Fig. 4. If hepara-
nase cleaves the linkage of -GlcA-GlcNS3S- orGlcA-GlcNS6S-,
we should observe a 35S-labeledmonosaccharide in the hepara-
nase-treated substrates followed by nitrous acid degradation,
whereas the monosaccharide should be absent in the substrate
without heparanase treatment. As expected, 35S-labeledmono-
saccharide in heparanase-treated substrates 4 and 5 was
observed as shown in Fig. 4, whereas nomonosaccharide can be
detected in the control sample. Our data suggest that hepara-
nase cleaves the linkage between GlcA and GlcNS6S (or -3S).
Our next goal was to determine whether heparanase cleaves
the linkage of -GlcA2S-GlcNS-, given the fact that substrate 6 is
susceptible to heparanase cleavage. We prepared 2-O-35S sul-
fated substrate 6 and utilized the same method as described
above with an intention to observe the 35S-labeled monosac-
charide. However, we did not detect any 35S-labeled monosac-
charide, suggesting that heparanase does not cleave the linkage
of -GlcA2S-GlcNS- directly (supplemental Fig. 4). We then
hypothesized that heparanase cleaves the linkage of GlcA-
GlcNS, whereas a GlcA2S unit is located in proximity. To this
end, N-35S sulfated substrate 6 was prepared. Substrate 6 was
treated with heparanase followed by the degradation with a
mixture of heparin lyases, and the products were analyzed by
BioGel P-2 (Fig. 5C). As shown in Fig. 5, a 35S-labeledmonosac-
charide ([35S]GlcNS) was observed in the heparanase-treated
sample, while this monosaccharide was absent in the substrate
without heparanase treatment. Taken together, our results
confirmed that heparanase does not cleave the linkage of
-GlcA2S-GlcNS- but rather cleaves the linkage of -GlcA-
GlcNS- nearby.
Polysaccharide 7, Containing -IdoA2S-GlcNS- Repeating
Unit, Inhibits the Activity of Heparanase—As demonstrated
above, polysaccharide 7, containing the repeating unit of
-IdoA2S-GlcNS-, is not a substrate for heparanase, whereas
substrate 6, containing -GlcA2S-GlcNS-, is a substrate. We
hypothesized that polysaccharide 7 could serve as an inhibitor
FIGURE 4. Determination of the heparanase cleavage sites within substrates 4 and 5. 35S-labeled substrates 4 and 5 were degraded with nitrous acid with
or without pretreatment of heparanase. The products were analyzed by BioGel P-2. Panel A shows the profile of substrate 4 with or without pretreatment of
heparanase. Panel B shows the profiles of substrate 5 with or without pretreatment of heparanase. Panel C depicts the reactions involved in the nitrous acid
degradation with or without pretreatment of heparanase. cpm, counts per min.
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for heparanase. The reactionswere then carried out in the pres-
ence of a range of concentrations (0.5–50g/ml) of substrate 7.
To demonstrate the structural selectivity, both substrates 3 and
2were also used. Substrate 3,with repeating disaccharide units
of GlcA-GlcNAc, did not inhibit the enzyme activity even at the
concentration of 50 g/ml (Fig. 6A). Similarly, the same result
was shown for substrate 2 with the repeating units of
GlcA-GlcNAc6S (data not shown). However, the activity of
heparanase was clearly affected by polysaccharide 7 in a dose-
responsivemanner (Fig. 6B). In fact, the addition of 50g/ml of
polysaccharide 7 caused complete inhibition of the enzymatic
activity. PI-88, a known inhibitor of heparanase, also exhibited
the inhibition effect under these conditions (Fig. 6C). The inhi-
bition potency of polysaccharide 7 was comparable to PI-88.
Collectively, these data concluded that the polysaccharide with
the repeating disaccharide structure IdoA2S-GlcNS could
serve as a heparanase inhibitor.
DISCUSSION
The journey for identifying and characterizing heparanase
has been long and less straightforward. The first mention of
heparanase in literature occurred in 1975 whenOgren and Lin-
dahl (38) reported the cleavage of heparin by an enzyme iso-
lated from themastocytomas of tumor bearingmice. Due to the
lack of a reliable assay for monitoring the degradation of
HS/heparin and a low abundance of heparanase, the cDNA of
heparanase remained unidentified for another two decades (21,
39–41). The substrate specificities of heparanase were con-
founded by the structural heterogeneity of HS polysaccharide
substrates. It largely was assumed that heparanase cleaves a
very specific sulfated monosaccharide sequence. Previously,
Pikas et al. (27) reported thatN-sulfo groups and IdoA units are
not required for substrate recognition, but O-sulfation on the
hexuronic acid is essential for the enzyme action. This study
also suggested that heparanase recognizes 2-O-sulfated hexu-
ronic units thatmay be either IdoAorGlcA.However, Okada et
al. (28) reported that the 2-O-sulfate group on the hexuronic
residue was not essential for enzyme action. Using an impres-
sive array of hexa- and tetrasaccharides, Okada et al. (28) con-
cluded that heparanase cleaves the linkage of -GlcA-GlcNS6S-.
However, it is still difficult to decipher the precise contribution
of each O-sulfation type to the susceptibility of heparanase,
largely due to the fact that the choice of oligosaccharides con-
tained multiple types of modifications. Furthermore, these oli-
gosaccharides did not cover all possible heparanase cleavable
linkages. To this end, whether heparanase recognizes single or
multiple monosaccharide sequences remains elusive.
In this article, we utilized synthesized polysaccharide sub-
strates with systematically varied sulfations to determine the
FIGURE 5. Determination of the heparanase cleavage sites within substrate 6. 35S-labeled substrate 6 was degraded with heparin lyases I, II, and III with or
without pretreatment of heparanase. The products were analyzed by BioGel P-2. It is worth noting that substrate 6 contains 35S-labeled N-sulfation and
unlabeled 2-O-sulfation. Panel A shows the profile of substrate 6 without pretreatment of heparanase. Panel B shows the profiles of substrate 6 with pretreat-
ment of heparanase. Panel C shows the reactions involved in the heparin lyase digestion with or without pretreatment of heparanase.
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effects of N-sulfation, 6-O-sulfation, 2-O-sulfation, and epi-
merization on the susceptibility of heparanase cleavage. Syn-
thetic polysaccharides offer several advantages. First, the
sulfation type is highly homogeneous due to the exclusive
regioselectivity of the biosynthetic enzymes. Such sulfation
selectivity was confirmed by the disaccharide analysis. Sec-
ond, the sulfation patterns in the synthetic polysaccharides are
present in nearly all theHS isolated fromnatural sources. Thus,
the synthetic polysaccharides represent the domain structures
of HS isolated from natural sources. Third, the length of
the synthetic polysaccharides is comparable to cellular HS. The
results of our substrate specificity studies should represent the
action of heparanase on cellular HS. In fact, the products of
heparanase-cleaved HS are mainly larger than decasaccharide
(supplemental Fig. 1). Thus, studies with polysaccharide sub-
strates should eliminate the potential artifacts using oligosac-
charide substrates. In our study, we found that the polysaccha-
rides containing -GlcA-GlcNS6S- and -GlcA-GlcNS3S- are
excellent substrates for heparanase. The effect of 6-O-sulfation
is consistent with previous findings using oligosaccharide sub-
strates (28). We also found that the polysaccharide with a
repeating unit of -GlcA-GlcNAc6S- is not a substrate, consis-
tent with the observation reported by Okada et al. (28) using an
oligosaccharide substrate that contains the linkage of
GlcA-GlcNAc6S. The effect of 2-O-sulfation on the hexuronic
acid (GlcA and IdoA) is somewhat surprising. Our data sug-
gested that the polysaccharide bearing the repeating unit of
-GlcA2S-GlcNS- is cleaved by heparanase. Although the struc-
ture of -GlcA2S-GlcNS- has been suggested by Pikas et al. (42)
using a chemically sulfatedN-sulfo heparosan, their conclusion
could be complicated by the presence of other types of sulfation
in the polysaccharide. Starkly different from -GlcA2S-GlcNS-,
the polysaccharide bearing IdoA2S-GlcNS is not a substrate
and serves as an inhibitor of heparanase.
Our results revealed the substrate specificity of heparanase,
which is summarized in Fig. 7. Heparanase cleaves the linkage
of a nonsulfated glucuronic acid and glucosamine carrying
N-sulfo or both N-sulfo and O-sulfo groups. Our model sug-
gests that the enzyme recognizes certain sulfation patterns
rather than specific sulfated monosaccharide sequences.
Heparanase recognizes theN-sulfo group as well as theO-sulfo
group at the glucosamine unit at1 site. In the case thatO-sul-
fation of glucosamine is absent, heparanase recognizes the
GlcA2S unit located at the 2 site for cleaving the substrate.
Alternatively, heparanase possibly recognizes the GlcA2S resi-
due located at the2 site.When replacing a GlcA2S unit at the
2 (or2) positionwith IdoA2S, the site is no longer a cleavage
FIGURE 6. Inhibition of the activity of heparanase. Panel A shows the GPC-
HPLC profiles of heparanase-treated 35S-labeled substrate in the presence of
different concentrations of N-sulfo heparosan (polysaccharide 3) as well as
the untreated 35S-labeled substrate. Panel B shows the GPC-HPLC profiles of
heparanase-treated 35S-labeled substrate in the presence of different con-
centrations of N-sulfo 2-O-sulfo heparan (polysaccharide 7) as well as the
untreated 35S-labeled substrate. Panel C shows the GPC-HPLC profiles of
heparanase-treated 35S-labeled substrate in the presence of different con-
centrations of PI-88 as well as the untreated 35S-labeled substrate. cpm,
counts per min.
FIGURE 7. Proposed heparanase substrate recognition sites. Heparanase
cleaves the linkage between a nonsulfated GlcA and GlcNS. If the 1 site is
3-O-sulfated or 6-O-sulfated, the enzyme cleaves. If the 1 site is not O-sul-
fated, the enzyme searches for the structure beyond the GlcNS at 1 or 1
site. It is possible to recognize the 2-O-sulfo group located at either the 2
site or at the 2 site.
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site for heparanase. In addition, replacing the N-sulfo group
with N-acetyl at the 1 position becomes resistant to hepara-
nase degradation. It should be noted that whether the GlcA2S
located beyond 2 or 2 site affects the susceptibility to the
heparanase cleavage remains to be determined.
The active role of heparanase in tumor metastasis has
attracted considerable interests in searching for an inhibitor
of heparanase via different mechanisms of action (11). A
number of chemical entities are known to inhibit the activity
of heparanase. Among them, sulfated oligosaccharides like
PI-88 have reached phase III clinical trials. Heparin is also a
potent inhibitor of heparanase (43, 44). However, the anti-
coagulant activity of heparin could cause an undesired bleeding
effect when used as an anticancer drug. Furthermore, heparin is
capable of displacing the growth factors that are sequestered by
the HS located in the extracellular matrix and consequently
stimulates cell proliferation. Thus, there is a strong demand to
maintain the activity for inhibiting heparanase while eliminat-
ing the anticoagulant or cell proliferation activities. Toward
this goal, a glycol split heparin-like polysaccharide was discov-
ered byNaggi et al. (45). Because the glycol split polysaccharide
contains unnatural saccharide units and there is no clear path-
way to degrade suchmolecule, it is a concern if it is accumulated
in the body as a long term anticancer therapeutic. Here, we
reported that a polysaccharide with the repeating unit of
-IdoA2S-GlcNS- can also serve as an inhibitor. It is known that
the polysaccharide carrying -IdoA2S-GlcNS- repeating se-
quence has no anticoagulant activity or the activity in stimulat-
ing cell proliferation (46). In fact, polysaccharide with -IdoA2S-
GlcNS- serves as an inhibitor for fibroblast growth factor/
HS-mediated cell proliferation activity (47), a favorable prop-
erty as an anticancer agent. Our next goal is to identify the
minimum saccharide structure carrying the -IdoA2S-GlcNS
repeat for inhibiting the activity of heparanase.
The findings of this study revealed the recognition pattern
of heparanase. The structural moiety recognized by hepara-
nase includes a GlcA unit and GlcNS unit carrying O-sulfa-
tions. The enzyme proved to be promiscuous in the aspect of
the type and location of O-sulfation required for recognition.
Furthermore, the polysaccharide containing GlcA2S renders
the susceptibility of heparanase cleavage. Our study also dis-
covered that IdoA2S-GlcNS may serve as an inhibitor of
heparanase enzymatic activity. The results should provide the
substrate specificity of heparanase needed for the design of an
effective inhibitor.
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